<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935662</url>
  </required_header>
  <id_info>
    <org_study_id>D2350C00001</org_study_id>
    <secondary_id>EudraCT No. 2009-010702-11</secondary_id>
    <nct_id>NCT00935662</nct_id>
  </id_info>
  <brief_title>A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses</brief_title>
  <official_title>A Randomised, Single-blind, Placebo-controlled, Two-centre Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD8329 After Single Ascending Oral Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective for this study is to assess the safety and tolerability of AZD8329 when
      given as a single dose in increasing dose strength, and also to identify the highest
      tolerated dose for future studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measurements (ECG's, Pulse, Blood Pressure, Safety Laboratory and Adverse Events)</measure>
    <time_frame>Safety will be monitored continously and safety assessments will be made on several occasions throughout the whole study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK samples for AZD8329</measure>
    <time_frame>Intense PK-sampling during the 24 hours following administration of investigational product and additional samples up to 72 hours after dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">119</enrollment>
  <condition>Healthy Men</condition>
  <arm_group>
    <arm_group_label>AZD8329</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD8329 oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for AZD8329 oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8329</intervention_name>
    <description>Oral solution, single ascending doses</description>
    <arm_group_label>AZD8329</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral solution, placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Have a body mass index between 19 and 30 kg/m2 and weigh at least 50 kg

        Exclusion Criteria:

          -  Any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or influence the result of the study, or the subject´s ability to participate

          -  Any clinically significant abnormalities in clinical chemistry, haematology or
             urinalysis results as judged by the investigator

          -  Any clinically important abnormalities in rhythm, conduction or morphology of resting
             ECG that may interfere with the interpretation of QTc interval changes.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Kühn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB, Phase I Services, Uppsala, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <last_update_submitted>September 10, 2010</last_update_submitted>
  <last_update_submitted_qc>September 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca R&amp;D Mölndal, Sweden</organization>
  </responsible_party>
  <keyword>First time in man</keyword>
  <keyword>Safety study</keyword>
  <keyword>AZD8329</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

